UCM Revenue Potential 2020, page-2

LiDCO is probably the most similar listed company to ours as they sell a similar product and our market caps are almost identical. But even then it's very difficult to find useful comparisons. Their revenue has also spiked (+179% Feb - Apr) due to the demand for haemodynamic monitors, mainly in the UK. They also recently entered China through distributors. They say sales in all areas other than the US have seen increased demand. I assume because the private system in the US got destroyed by the pause on elective surgeries.

Annual report talking about impact of Covid.
http://www.lidco.com/wp-content/uploads/2020/04/LiDCO_AR_2019-20_final.pdf

Q1 sales update for Covid. Discusses European support for haemodynamic monitoring
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/LID/14527872.html

I initially thought their market cap seems cheap compared to ours based on revenue at almost double but even with good "margins" their admin expenses are incredibly bloated and their third party product business recently got hit. Noting their product is structured as a "platform" so recurring revenue and not monitor sales are the driving force and thus their gross margin seems very slippery.

So even if we're very skeptical of what UCM says there clearly has already been a worldwide increased demand for haemodynamic monitors at least in the short term and the US isn't going to impact much any time soon.

Your post inspired me to quickly dive into their recent results so I've likely missed or misread a bit.